Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 6.9% – Here’s Why

by · The Markets Daily

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report)’s share price traded up 6.9% during mid-day trading on Friday . The company traded as high as $35.81 and last traded at $35.1130. 787,380 shares changed hands during trading, a decline of 16% from the average session volume of 942,807 shares. The stock had previously closed at $32.85.

Wall Street Analyst Weigh In

Several equities research analysts have commented on GPCR shares. Lifesci Capital upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. Guggenheim reduced their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, August 7th. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Structure Therapeutics in a research note on Friday, November 28th. JMP Securities reduced their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Finally, Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research note on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $68.67.

Check Out Our Latest Report on Structure Therapeutics

Structure Therapeutics Price Performance

The firm has a 50 day moving average of $31.19 and a 200-day moving average of $24.22. The stock has a market capitalization of $1.99 billion, a P/E ratio of -28.25 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, equities analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of large investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. bought a new position in Structure Therapeutics in the 3rd quarter valued at $6,856,000. Paradigm Biocapital Advisors LP bought a new position in shares of Structure Therapeutics in the third quarter valued at about $10,440,000. Mariner LLC lifted its position in Structure Therapeutics by 11.7% during the 3rd quarter. Mariner LLC now owns 44,136 shares of the company’s stock worth $1,236,000 after buying an additional 4,635 shares in the last quarter. National Bank of Canada FI grew its holdings in Structure Therapeutics by 71,900.0% during the 3rd quarter. National Bank of Canada FI now owns 144,000 shares of the company’s stock worth $4,032,000 after acquiring an additional 143,800 shares during the last quarter. Finally, Millennium Management LLC increased its position in Structure Therapeutics by 4.5% in the 3rd quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after acquiring an additional 54,496 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Featured Stories